Hodgkin lymphoma: Response assessment by Revised International Workshop Criteria

Leukemia and Lymphoma

Volumn 48, Issue 8, 2007, Pages 1539-1547

  Brepoels, Lieselot ^a   Stroobants, Sigrid ^a   de Wever, Walter ^a   Spaepen, Karoline ^a   Vandenberghe, Peter ^a   Thomas, Jose ^a   Uyttebroeck, Anne ^a   Mortelmans, Luc ^a   de Wolf Peeters, Christiane ^a   Verhoef, Gregor ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

CT; Hodgkin's lymphoma; PET; Response assessment

Indexed keywords

BLEOMYCIN; CHLORMETHINE; DOXORUBICIN; FLUORODEOXYGLUCOSE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CANCER RELAPSE; CLASSIFICATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; WORKSHOP;

ADOLESCENT; ADULT; AGED; CHILD; FEMALE; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; INTERNATIONAL COOPERATION; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; POSITRON-EMISSION TOMOGRAPHY; PRACTICE GUIDELINES; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 34547972405     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701422414     Document Type: Article

References (25)

1. Jochelson, M., Mauch, P., Balikan, J., Rosenthal, D. and Canellos, G. (1985) The significance of the residual mediastinal mass in treated Hodgkin's disease. J Clin Oncol, 3, pp. 637-640.
2. Loeffler, M., Brosteanu, O., Hasenclever, D., Sextro, M., Assouline, D. and Bartolucci, A. A. (1998) Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. J Clin Oncol, 16, pp. 818-829.
3. Meyer, R. M., Gospodarowicz, M. K., Connors, J. M., Pearcey, R. G., Bezjak, A. and Wells, W. A. (2005) Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol, 23, pp. 4634-4642.
4. Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I. and Connors, J. M. (1999) Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas. J Clin Oncol, 17, pp. 1244-1253.
5. Eghbali, H., Brice, P., Creemers, G. Y., Kooij, M Van Marwijk, Carde, P. and Veer, M B Van't (2005) Comparison of three radiation dose levels after EBVP regimen in favorable supradiaphragmatic clinical stages (CS) I-II Hodgkin's lymphoma (HL): Preliminary results of the EORTC-GELA H9-F trial. Blood, 106
6. Spaepen, K., Stroobants, S., Dupont, P., Van Steenweghen, S., Thomas, J. and Vandenberghe, P. (2001) Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: Is [18F]FDG-PET a valid alternative to conventional diagnostic methods?. J Clin Oncol, 19, pp. 414-419.
7. Jerusalem, G., Beguin, Y., Fassotte, M. F., Najjar, F., Paulus, P. and Rigo, P. (1999) Whole-body positron emission tomography using 18F-fluorodeoxyglucose for post-treatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed classical computed tomography scan imaging. Blood, 94, pp. 429-433.
8. Naumann, R., Vaic, A., Beuthien-Baumann, B., Bredow, J., Kropp, J. and Kittner, T. (2001) Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br J Haematol, 115, pp. 793-800.
9. Zinzani, P. L., Fanti, S., Battista, G., Tani, M., Castellucci, P. and Stefoni, V. (2004) Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. Br J Cancer, 91, pp. 850-854.
10. Mikhaeel, N. G., Timothy, A. R., O'Doherty, M. J., Hain, S. and Maisey, M. N. (2000) 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma-comparison with CT. Leuk Lymphoma, 39, pp. 543-553.
11. Cheson, B. D., Pfistner, B., Juweid, M. E., Gascoyne, R. D., Specht, L. and Horning, S. J. (2007) Revised response criteria for malignant lymphoma. J Clin Oncol, 25:5, pp. 579-586.
12. Juweid, M. E., Stroobants, S., Hoekstra, O. S., Mottaghy, F. M., Dietlein, M. and Guermazi (2007) Use of positron emission tomography (PET) for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project (IHP) in Lymphoma. J Clin Oncol, 25:5, pp. 571-578.
13. Spaepen, K., Stroobants, S., Dupont, P., Thomas, J., Vandenberghe, P. and Balzarini, J. (2001) Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?. Br J Haematol, 115, pp. 272-278.
14. Armitage, J. (2005) Staging non-Hodgkin lymphoma. CA Cancer J Clin, 55, pp. 368-376.
15. Horning, S. J., Williams, J., Bartlett, N. L., Bennett, J. M., Hoppe, R. T. and Neuberg, D. (2000) Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group pilot study E1492. J Clin Oncol, 18, pp. 972-980.
16. Glick, J. H., Young, M. L., Harrington, D., Schilsky, R. L., Beck, T. and Neiman, R. (1998) MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: The 8-year results of the intergroup trial. J Clin Oncol, 16, pp. 19-26.
17. Kaplan, E. S. and Meier, P. (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc, 58, pp. 457-481.
18. Hueltenschmidt, B., Sautter-Bihl, M. L., Lang, O., Maul, F. D., Fischer, J. and Mergenthaler, H. G. (2001) Whole body positron emission tomography in the treatment of Hodgkin disease. Cancer, 91, pp. 302-310.
19. Weihrauch, M. R., Scheidhauer, K., Ansen, S., Dietlein, M. and Bischoff, S. (2001) Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood, 98, pp. 2930-2934.
20. de Wit, M., Bohuslavizki, K. H., Buchert, R., Bumann, D., Clausen, M. and Hossfeld, D. K. (2001) 18FDG-PET following treatment as valid predictor for disease-free survival I Hodgkin's disease. Ann Oncol, 12, pp. 29-37.
21. Lavely, W. C., Delbeke, D., Greer, J. P., Morgan, D. S., Byrne, D. W. and Price, R. R. (2003) FDG PET in the follow-up management of patients with newly diagnosed Hodgkin and non-Hodgkin lymphoma after first-line chemotherapy. Int J Radiat Oncol Biol Phys, 57, pp. 307-315.
22. Guay, C., Lepine, M., Verreault, J. and Benard, F. (2003) Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation. J Nucl Med, 44, pp. 1225-1231.
23. Jerusalem, G., Beguin, Y., Fassotte, M. F., Belhocine, T., Hustinx, R. and Rigo, P. (2003) Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol, 14, pp. 123-130.
24. Friedberg, J. W., Fischman, A., Neuberg, D., Kim, H., Takvorian, T. and Ng, A. K. (2004) FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: A blinded comparison. Leuk Lymphoma, 45, pp. 85-92.
25. Panizo, C., Perez-Salazar, M., Bendandi, M., Rodriguez-Calvillo, M., Boan, J. F. and Garcia-Velloso, M. J. (2004) Positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual Hodgkin's disease mediastinal masses. Leuk Lymphoma, 45, pp. 1829-1833.